Hey, Fantomphan... Although you have been taking grief from fellow posters for your openness, thanks for telling it like it is in your own words. You vocalize frustrations that I'm sure others also feel who have been here and believe in the product for a long time. Your question is a good one, worthy of discussion. The more the merrier to help us focus on what is around the corner. Personally, with the recent breakthrough designation for the removal of Ticagrelor and the current on going talks with the FDA and our new CMO, I think we will be hearing very soon some positive results of those meetings that will have a profound effect on the fortune and direction going into our future.
Sidebar: Regarding our new CMO. In my opinion, this appointment, of
Dr. Efthymios “Makis” Deliargyris, will be looked back upon as an inflection point for the company. Everyone reading this, I ask you to take a moment and review Dr. Makis's bio, in the Executive Management section of "About" at Cytosorbents.com. We have heard him speak now several times, and each time I listen, I hear a confident, highly intelligent leader who has an excellent grasp of what we have to offer. He is exactly what we have been needing to help direct and present the face of Cytosorbents.
Hemodefend... This is big. There have been attempts to create in the laboratory artificial blood/plasma, having universal attributes. So far, this has failed to become commercially viable. Hemodefend could be the golden key to unlock that door to a universal blood supply. I expect it won't be too long before we hear from Dr. Chan regarding developments of Hemodefend, considering the financial infusion specifically for this program. Someone sees something worthwhile to fill a huge need in this lifesaving space.
Yes, the momentum may be waning, but only temporarily... I see a Darwinian effect in store for the shorts that fail to be nimble with CTSO.
News 
Market Data 
Discover 
